Skip to main content Accessibility help
×
×
Home

Clinical Perspectives on the Combination of D-Cycloserine and Cognitive-Behavioral Therapy for the Treatment of Anxiety Disorders

  • Michael W. Otto, Shawnee L. Basden, Teresa M. Leyro, R. Kathryn McHugh and Stefan G. Hofmann...

Abstract

In a particular success for translational research agendas, characterization of the neuronal circuits underlying fear extinction, and basic research in animal extinction paradigms, has led to intervention studies examining the use of D-cycloserine (DCS) to enhance therapeutic learning from exposure-based cognitive-behavioral therapy (CBT). In this article, we review these intervention studies, and discuss DCS augmentation of CBT relative to more traditional combination-treatment strategies in the treatment of anxiety disorders. We offer an accounting, based on evidence for internal context effects, of current limitations in the combination of antidepressant or benzodiazepine medications with CBT and discuss the advantages of isolated-dosing strategies with DCS relative to these limitations. This strategy is contrasted with the chronic-dosing applications of DCS for schizophrenia and Alzheimer's disease, and future directions for isolated-dosing strategies are discussed.

Copyright

Corresponding author

Please direct all correspondence to: Michael W. Otto, PhD, Boston University, Department of Psychology, Center for Anxiety and Related Disorders, 648 Beacon Street, Floor 6, Boston, MA 02215; Tel: 617-353-9610, Fax: 617-353-9609.

References

Hide All
1.Foa, EB, Franklin, ME, Moser, J. Context in the clinic: How well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry. 2002;10:987997.
2.Otto, MW, Smits, JAJ, Reese, HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clinical Psychology: Science and Practice. 2005;12:7286.
3.Davidson, JR, Foa, EB, Huppert, JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry. 2004;61:10051013.
4.Foa, EB, Liebowitz, MR, Kozak, MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry. 2005;162:151161.
5.van Balkom, AJ, de Haan, E, van Oppen, P, et al. Cognitive and behavioral therapies alone and in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis. 1998;186:492499.
6.Franklin, ME, Abramowitz, JS, Bux, DA, Zoellner, LA, Feeny, NC. Cognitive-behavioral therapy with and without medication in the treatment of obsessive-compulsive disorder. Professional Psychology: Research and Practice. 2002;33:162168.
7.Kampman, M, Keijsers, GP, Hoogduin, CA, Hendriks, GJ. A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry. 2002;63:772777.
8.Otto, MW, Pollack, MH, Penava, SJ, Zucker, BG. Cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: a clinical case series. Behav Res Ther. 1999;37:763770.
9.Heldt, E, Gus Manfro, G, Kipper, L, Blaya, C, Isolan, L, Otto, MW. One-year follow-up of pharmacotherapy-resistant patients with panic disorder treated with cognitive-behavior therapy: outcome and predictors of remission. Behav Res Ther. 2006;44:657665.
10.Barlow, DH, Gorman, JM, Shear, MK, Woods, SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA. 2000;283:25292536.
11.de Beurs, E, van Balkom, AJ, Lange, A, Koele, P, van Dyke, R. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry. 1995;152:683691.
12.Furukawa, TA, Watanabe, N, Chruchill, R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia. Br J Psychiatry. 2006;188:305312.
13.Marks, IM, Swinson, RP, Basaglu, M, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia: a controlled study in London and Toronto. Br J Psychiatry. 1993;162:776787.
14.Powers, MB, Smits, JAJ, Leyro, TM, Otto, M. Translational research perspectives on maximizing the effectiveness of exposure therapy. In: Richard, DCS, Lauterbach, D, eds. Comprehensive Handbook of the Exposure Therapies. Orlando, FL: Academic Press; 2006:109126.
15.Bouton, ME. Context, ambiguity, and unlearning: sources of relapse after behavioral extinction. Biol Psychiatry. 2002;52:976986.
16.Bouton, ME. Context and behavioral processes in extinction. Learn Mem. 2004;11:485494.
17.Bouton, ME, Kenney, FA, Rosengard, C. State dependent fear extinction with two benzodiazepine tranquilizers. Behav Neurosci. 1990;104:4455.
18.Rescorla, RA. Experimental extinction. In: Mowrer, RR, Klein, SB, eds. Handbook of Contemporary Learning Theories. Mahwah, NJ: Erlbaum; 2001:119154.
19.Mystkowski, JL, Mineka, S, Vernon, LL, Zinbarg, RE. Changes in caffeine states enhance return of fear in spider phobia. J Consult Clin Psychol. 2003;71:243250.
20.Foa, EB, Kozak, MJ. Emotional processing of fear: exposure to corrective information. Psychol Bull. 1986;99:2035.
21.Powers, MB, Smits, JA, Telch, MJ. Disentangling the effects of safety-behavior utilization and safety-behavior availability during exposure-based treatment: a placebo-controlled trial. J Consult Clin Psychol. 2004;72:448454.
22.Kamphuis, JH, Telch, MJ. Effect of distraction and guided threat reappraisal on fear reduction during exposure-based treatments for specific fears. Behav Res Ther. 2000;38:11631181.
23.Rodriguez, BI, Craske, MG. The effects of distraction during exposure to phobic stimuli. Behav Res Ther. 1993;31:549558.
24.Otto, MW, Pollack, MH, Sabatino, SA. Maintenance of remission following cognitive-behavior therapy for panic disorder: possible deleterious effects of concurrent medication treatment. Behav Ther. 1996;27:473482.
25.Davis, M, Falls, WA, Gewirtz, J. Neural systems involved in fear inhibition: extinction and conditioned inhibition. In: Myslobodsky, M, Weiner, I, eds. Contemporary Issues in Modeling Psychopathology. Boston, Mass: Kluwer Academic Publishers; 2000:113142.
26.Davis, M, Myers, KM. The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy. Biol Psychiatry. 2002;52:9981007.
27.Davis, M, Myers, KM, Ressler, KJ, Rothbaum, BO. Facilitation of extinction of conditioned fear by D-cycloserine: implications for psychotherapy. Current Directions in Psychological Science. 2005;14:214219.
28.Richardson, R, Ledgerwood, L, Cranney, J. Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learn Mem. 2004;11:510516.
29.Ledgerwood, L, Richardson, R, Cranney, J. D-cycloserine facilitates extinction of learned fear: effects of reacquisition and generalized extinction. Biol Psychiatry. 2005;57:841847.
30.Ressler, KJ, Rothbaum, BO, Tannenbaum, L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobics to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61:11361144.
31.Nair, K, Epstein, I, Baron, H, Mulinos, M. Absorption, distribution, and excretion of cycloserine in man. Antibiot Ann. 1956:136140.
32.D'Souza, DC, Gil, R, Cassello, K, et al. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol Psychiatry. 2000;47:450462.
33.Hofmann, SG, Meuret, AE, Smits, JAJ, et al. Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006;63:298304.
34.Katzelnick, DJ, Kobak, KA, DeLeire, T, et al. Impact of generalized social anxiety disorder in managed care. Am J Psychiatry. 2001;158:19992007.
35.Schneier, FR, Heckelman, LR, Garfinkel, R, et al. Functional impairment in social phobia. J Clin Psychiatry. 1994;55:322331.
36.Heresco-Levy, U, Kremer, I, Javitt, DC, et al. Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol. 2002;5:301307.
37.van Berckel, BN, Lipsch, C, Timp, S, et al. Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology. 1997;16:317324.
38.van Berckel, BN, Lipsch, C, Gispen-de Wied, C, et al. The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology (Berl). 1998;138:190197.
39.Physicians Desk Reference. 60th ed. Montvale, NJ: Thomson PDR: 2006.
40.Quartermain, D, Mower, J, Rafferty, MF, Herting, RL, Lanthorn, TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol. 1994;157:712.
41.Parnas, AS, Weber, M, Richardson, R. Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem. 2005;83:224231.
42.Boje, KM, Wong, G, Skolnick, P. Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res. 1993;603:207214.
43.Randolph, C, Roberts, JW, Tierney, MC, Bravi, D, Mouradian, MM,Chase, TN. D-cycloserine treatment of Alzheimer disease. Alzheimer Dis Assoc Disord. 1994;8:198205.
44.Tuominen, HJ, Tiihonen, J, Wahlbeck, K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophrenia Res. 2005;72:225234.
45.Evins, AE, Amico, E, Posever, TA, Toker, R, Goff, DC. D-cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophrenia Res. 2002;56:1923.
46.Goff, DC, Tsai, G, Manoach, DS, Coyle, JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms of schizophrenia. Am J Psychiatry. 1995;152:12131215.
47.Goff, DC, Coyle, JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry. 2001;158:13671377.
48.Goff, DC, Tsai, G, Levitt, J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1996;56:2127.
49.Duncan, EJ, Szilagyi, S, Schwartz, MP, et al. Effects of D-cycloserine on negative symptoms of schizophrenia. Schizophrenia Res. 2004;71:239248.
50.Goff, DC, Herz, L, Posever, T, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychpharmacology. 2005;179:144150.
51.Goff, DC. Tsai, G, Manoach, DS, et al. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 1996;153:16281630
52.van Berckel, BN, Hijman, R, van der Linden, JA, Westenberg, HG, van Ree, JM, Kahn, RS. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry. 1996;40:12981300.
53.Heresco-Levy, U, Javitt, DC, Ermilov, M, Silipo, G, Shimoni, J. Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol. 1998;1:131135.
54.Goff, DC, Henderson, DC, Evins, E, Amico, E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry. 1999;45:512514.
55.Heresco-Levy, U, Ermilov, M, Shimoni, J, Shapira, B, Silipo, G, Javitt, DC. Placebo-controlled trial of D-cylcoserine added to cconventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry. 2002;159:480482.
56.Rosse, RB, Fay-McCarthy, M, Kendrick, K, Davis, RE, Deutsch, SI. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia. Clin Neuropharmacol. 1996;19:444450.
57.van Berckel, BN, Evenblij, CN, van Loon, AM, et al. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology. 1999;21:203210.
58.Yurgelun-Todd, DA, Coyle, JTGruber, SA, et al. Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine. Psychiatry Res. 2005;138:2331.
59.Tsai, GE, Falk, WE, Gunther, J, Coyle, JT. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment. Am J Psychiatry. 1999;156:467469.
60.Fakouhi, TD, Jhee, SS, Sramek, JJ, et al. Evaluation of cycloserine in the treatment of Alzheimer's disease. J Geriatr Psychiatry Neurol. 1995;8:226230.
61.Tsai, GE, Falk, WE, Gunther, J. A preliminary study of d-cycloserine treatment in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1998;10:224226.
62.Laake, JR, Oeksengaard, AR. D-cycloserine for Alzheimer's disease. (Cochrane Review). The Cochrane Database of Systematic Reviews. 2002, Issue 2. Art. No.: CD003153. DOI:10.1002/14651858.CD003153.
63.Ledgerwood, L, Richardson, R, Cranney, J. Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci. 2003;117:341349.
64.Barlow, DH, ed. Clinical Handbook of Psychological Disorders. 3rd ed. New York: Guilford Press; 2001.
65.Hofmann, SG, Tompson, MC, eds. Treating Chronic and Severe Mental Disorders: A Handbook of Empirically Supported Interventions. New York, NY: Guilford Press; 2002.
66.Land, C, Riccio, D. D-cycloserine: effects on long-term retention of a conditioned response and on memory for contextual attributes. Neurobiol Learn Mem. 1999;72:158168.
67.Pussinen, R, Sirvio, J. Effects of D-cycloserine, a positive modulator of N-methyl-D-aspartate receptors, and ST 587, a putative alpha-1 adrenergic agonist, individually and in combination, on the non-delayed and delayed foraging behaviour of rats assessed in the radial arm maze. J Psychopharmacol. 1999;13:171179.
68.Lelong, V, Dauphin, F, Boulouard, M. RS 67333 and D-cycloserine accelerate learning acquisition in the rat. Neuropharmacology. 2001;41:517522.
69.Pitkanen, M, Sirvio, J, MacDonald, E, Niemi, S, Ekonsalo, T, Riekkinen, P Sr. European Neuropsychopharmacology. 1995;5:457–63.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed